Stockreport

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis [Yahoo! Finance]

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com
PDF All three doses met the primary endpoint of clinical response at Week 12, with a favorable safety profile These results in ulcerative colitis build on strong data rec [Read more]